Xinlai Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xinlai Cheng has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
- Stefan Wölfl
Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Im Neuenheimer Feld 364, 69120 Heidelberg, Germany
18 shared publications Gerhard Eisenbrand
Department of Chemistry, Division of Food Chemistry and Toxicology, University of Kaiserslautern , Erwin-Schrödinger-Strasse 52, D-67663 Kaiserslautern, Germany
10 shared publicationsKarl-Heinz Merz
Department of Chemistry, Division of Food Chemistry and Toxicology, University of Kaiserslautern , Erwin-Schrödinger-Strasse 52, D-67663 Kaiserslautern, Germany
8 shared publicationsStefan Wölfl
Department of Pharmacy and Molecular Biotechnology, Division of Pharmaceutical Biology, University of Heidelberg, Im Neuenheimer Feld 364, D-69120, Heidelberg, Germany
7 shared publications- Ralf Mrowka
Department of Internal Medicine III, Experimental Nephrology, Jena University Hospital, Jena, Germany
6 shared publications Yasamin Dabiri
Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany 2
6 shared publications
Latest Publications
- Open Access
- 21 December 2025
- Published by Wiley in Angewandte Chemie
- Vol. 138 (5)
Gezielte Modulation des spliceosomalen Proteins USP39 durch allosterische Liganden und PROTAC‐induzierte Degradation
Zusammenfassung: Die präzise Regulation der Genexpression ist grundlegend für die zelluläre Homöostase und Diversität. Eine Fehlregulation des Spleißvorgangs ist mit verschiedenen pathologischen Krankheiten, einschließlich Tumorentstehung und neurodegenerativen Erkrankungen, assoziiert. Die Ubiquitin‐spezifische Protease 39 (USP39) ist ein essenzieller, jedoch katalytisch inaktiver Bestandteil des Spliceosoms und gilt daher als schwer zugängliches pharmakologisches Ziel. In dieser Studie identifizierten wir thiazolbasierte Liganden, die selektiv an USP39 binden und bevorzugt mit dessen Zinkfinger‐Domäne interagieren. AlphaFold‐gestützte Struktur‐Wirkungs‐Analysen ermöglichten die rationale Weiterentwicklung dieser Liganden zu Proteolyse‐targeting‐Chimären (PROTACs), einschließlich USP39_PROTAC_V1, das die von Hippel–Lindau‐(VHL)‐E3‐Ligase zur gezielten Proteindegradation rekrutiert. Biophysikalische und biochemische Untersuchungen belegten eine effiziente ternäre Komplexbildung sowie Bindungsaffinitäten im nanomolaren Bereich. Die entwickelten PROTACs führten in zellulären Assays bereits bei 1 nM zu einer ausgeprägten, proteomweit bestätigten, selektiven Degradation von USP39. Mechanistische Untersuchungen ergaben, dass die Degradation von der VHL‐Rekrutierung abhängig ist und durch eine Hemmung des Proteasoms oder der Neddylierung vollständig blockiert wurde. Die funktionelle Depletion von USP39 führte zu charakteristischen 5'‐Spleißstellen‐spezifischen Spleißmustern und bestätigt sowohl den zugrunde liegenden Wirkmechanismus als auch den potenzielle therapeutische Nutzen dieses Ansatzes – insbesondere zur Modulation spleißassoziierter Krankheitswege wie Krebs und Retinitis pigmentosa.
- 21 December 2025
- Published by Wiley in Angewandte Chemie
- Vol. 138 (5)
Open AccessGezielte Modulation des spliceosomalen Proteins USP39 durch allosterische Liganden und PROTAC‐induzierte Degradation
Zusammenfassung: Die präzise Regulation der Genexpression ist grundlegend für die zelluläre Homöostase und Diversität. Eine Fehlregulation des Spleißvorgangs ist mit verschiedenen pathologischen Krankheiten, einschließlich Tumorentstehung und neurodegenerativen Erkrankungen, assoziiert. Die Ubiquitin‐spezifische Protease 39 (USP39) ist ein essenzieller, jedoch katalytisch inaktiver Bestandteil des Spliceosoms und gilt daher als schwer zugängliches pharmakologisches Ziel. In dieser Studie identifizierten wir thiazolbasierte Liganden, die selektiv an USP39 binden und bevorzugt mit dessen Zinkfinger‐Domäne interagieren. AlphaFold‐gestützte Struktur‐Wirkungs‐Analysen ermöglichten die rationale Weiterentwicklung dieser Liganden zu Proteolyse‐targeting‐Chimären (PROTACs), einschließlich USP39_PROTAC_V1, das die von Hippel–Lindau‐(VHL)‐E3‐Ligase zur gezielten Proteindegradation rekrutiert. Biophysikalische und biochemische Untersuchungen belegten eine effiziente ternäre Komplexbildung sowie Bindungsaffinitäten im nanomolaren Bereich. Die entwickelten PROTACs führten in zellulären Assays bereits bei 1 nM zu einer ausgeprägten, proteomweit bestätigten, selektiven Degradation von USP39. Mechanistische Untersuchungen ergaben, dass die Degradation von der VHL‐Rekrutierung abhängig ist und durch eine Hemmung des Proteasoms oder der Neddylierung vollständig blockiert wurde. Die funktionelle Depletion von USP39 führte zu charakteristischen 5'‐Spleißstellen‐spezifischen Spleißmustern und bestätigt sowohl den zugrunde liegenden Wirkmechanismus als auch den potenzielle therapeutische Nutzen dieses Ansatzes – insbesondere zur Modulation spleißassoziierter Krankheitswege wie Krebs und Retinitis pigmentosa.
- Open Access
- 21 December 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (5) , e16809
Targeting the Spliceosomal Protein USP39 Through Allosteric Ligands and PROTAC‐Induced Degradation
The precise regulation of gene expression is fundamental to cellular homeostasis and diversity. Dysregulation of splicing has been implicated in a range of diseases, including cancer and neurodegeneration. Ubiquitin‐specific protease 39 (USP39), an essential spliceosome component lacking enzymatic activity, has remained an elusive target for pharmacological intervention. Here, we report the discovery of small‐molecule ligands that selectively engage with USP39 through a thiazole scaffold, primarily interacting with its zinc finger domain. Guided by AlphaFold‐based structure–activity relationship studies, we designed and optimized proteolysis‐targeting chimeras (PROTACs), culminating in the development of USP39_PROTAC_V1, which harnesses the von Hippel–Lindau (VHL) E3 ubiquitin ligase for targeted degradation. Biophysical and biochemical assays demonstrated potent ternary complex formation and nanomolar‐range binding affinities. In cellular models, USP39_PROTACs achieved efficient degradation of USP39 at concentrations as low as 1 nM, with minimal off‐target effects as confirmed by proteome‐wide profiling. Mechanistic studies revealed that degradation was dependent on VHL recruitment and was abrogated by proteasome or neddylation inhibition. Notably, USP39 depletion recapitulated 5′‐splice‐site‐specific splicing patterns previously described, thereby validating both the mechanism of action and the therapeutic relevance of this approach—particularly for modulating splicing‐associated disease pathways such as cancer and retinitis pigmentosa.
- 21 December 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (5) , e16809
Open AccessTargeting the Spliceosomal Protein USP39 Through Allosteric Ligands and PROTAC‐Induced Degradation
The precise regulation of gene expression is fundamental to cellular homeostasis and diversity. Dysregulation of splicing has been implicated in a range of diseases, including cancer and neurodegeneration. Ubiquitin‐specific protease 39 (USP39), an essential spliceosome component lacking enzymatic activity, has remained an elusive target for pharmacological intervention. Here, we report the discovery of small‐molecule ligands that selectively engage with USP39 through a thiazole scaffold, primarily interacting with its zinc finger domain. Guided by AlphaFold‐based structure–activity relationship studies, we designed and optimized proteolysis‐targeting chimeras (PROTACs), culminating in the development of USP39_PROTAC_V1, which harnesses the von Hippel–Lindau (VHL) E3 ubiquitin ligase for targeted degradation. Biophysical and biochemical assays demonstrated potent ternary complex formation and nanomolar‐range binding affinities. In cellular models, USP39_PROTACs achieved efficient degradation of USP39 at concentrations as low as 1 nM, with minimal off‐target effects as confirmed by proteome‐wide profiling. Mechanistic studies revealed that degradation was dependent on VHL recruitment and was abrogated by proteasome or neddylation inhibition. Notably, USP39 depletion recapitulated 5′‐splice‐site‐specific splicing patterns previously described, thereby validating both the mechanism of action and the therapeutic relevance of this approach—particularly for modulating splicing‐associated disease pathways such as cancer and retinitis pigmentosa.
- Open Access
- 22 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 22633-22649
A Chemically Induced CRISPR/dCas13 FCPF Platform for Precise and Programmable RNA Regulation
Alternative splicing enhances proteomic diversity, yet its dysregulation drives cancer, neurodegeneration, and inherited disease. Small-molecule splicing modulators, while clinically validated, like risdiplam, often lack locus specificity, producing off-target effects. CRISPR/Cas13 enables programmable transcript-level targeting, but dCas13 fusion effectors are bulky and can hamper delivery and RNA homeostasis. Building on our previous Chem-CRISPR/dCas9FCPF system for epigenome editing, we now introduce Chem-CRISPR/dCas13FCPF, a modular platform that covalently tethers a perfluorobiphenyl-tagged small molecule to dCas13 via a four-residue FCPF π-clamp tag. Guided by crRNAs, dRfxCas13dFCPF recruits a risdiplam-derived conjugate to the SMN2 exon 7 splice region, inducing exon inclusion at ligand doses ∼500-fold lower than those of free risdiplam and with no detectable effects at known risdiplam-sensitive transcripts in our assays. The approach generalizes to additional transcripts by crRNA redesign. By coupling CRISPR addressability with dose-sparing chemical action, Chem-CRISPR/dCas13FCPF establishes a proximity-induced, chemically controllable route to precise RNA modulation suitable for therapeutic exploration.
- 22 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 22633-22649
Open AccessA Chemically Induced CRISPR/dCas13 FCPF Platform for Precise and Programmable RNA Regulation
Alternative splicing enhances proteomic diversity, yet its dysregulation drives cancer, neurodegeneration, and inherited disease. Small-molecule splicing modulators, while clinically validated, like risdiplam, often lack locus specificity, producing off-target effects. CRISPR/Cas13 enables programmable transcript-level targeting, but dCas13 fusion effectors are bulky and can hamper delivery and RNA homeostasis. Building on our previous Chem-CRISPR/dCas9FCPF system for epigenome editing, we now introduce Chem-CRISPR/dCas13FCPF, a modular platform that covalently tethers a perfluorobiphenyl-tagged small molecule to dCas13 via a four-residue FCPF π-clamp tag. Guided by crRNAs, dRfxCas13dFCPF recruits a risdiplam-derived conjugate to the SMN2 exon 7 splice region, inducing exon inclusion at ligand doses ∼500-fold lower than those of free risdiplam and with no detectable effects at known risdiplam-sensitive transcripts in our assays. The approach generalizes to additional transcripts by crRNA redesign. By coupling CRISPR addressability with dose-sparing chemical action, Chem-CRISPR/dCas13FCPF establishes a proximity-induced, chemically controllable route to precise RNA modulation suitable for therapeutic exploration.
- Open Access
- 26 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-33
Evolutionary divergence in CTCF-mediated chromatin topology drives transcriptional innovation in humans
Chromatin topology can impact gene regulation, but how evolutionary divergence in chromatin topology has shaped gene regulatory landscapes for distinctive human traits remains poorly understood. CTCF sites determine chromatin topology by forming domains and loops. Here, we show evolutionary divergence in CTCF-mediated chromatin topology at the domain and loop scales during primate evolution, elucidating distinct mechanisms for shaping regulatory landscapes. Human-specific divergent domains lead to a broad rewiring of transcriptional landscapes. Divergent CTCF loops concord with species-specific enhancer activity, influencing enhancer connectivity to target genes in a concordant yet constrained manner. Under this concordant mechanism, we establish the role of human-specific CTCF loops in shaping transcriptional isoform diversity, with functional implications for disease susceptibility. Furthermore, we validate the function of these human-specific CTCF loops using human forebrain organoids. This study advances our understanding of genetic evolution from the perspective of genome architecture.
- 26 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-33
Open AccessEvolutionary divergence in CTCF-mediated chromatin topology drives transcriptional innovation in humans
Chromatin topology can impact gene regulation, but how evolutionary divergence in chromatin topology has shaped gene regulatory landscapes for distinctive human traits remains poorly understood. CTCF sites determine chromatin topology by forming domains and loops. Here, we show evolutionary divergence in CTCF-mediated chromatin topology at the domain and loop scales during primate evolution, elucidating distinct mechanisms for shaping regulatory landscapes. Human-specific divergent domains lead to a broad rewiring of transcriptional landscapes. Divergent CTCF loops concord with species-specific enhancer activity, influencing enhancer connectivity to target genes in a concordant yet constrained manner. Under this concordant mechanism, we establish the role of human-specific CTCF loops in shaping transcriptional isoform diversity, with functional implications for disease susceptibility. Furthermore, we validate the function of these human-specific CTCF loops using human forebrain organoids. This study advances our understanding of genetic evolution from the perspective of genome architecture.
- Open Access
- 24 September 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (19) , 11587-11601
Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing
Epigenetic aberration is one of the major driving factors in human cancer, often leading to acquired resistance to chemotherapies. Various small molecule epigenetic modulators have been reported. Nonetheless, outcomes from animal models and clinical trials have underscored the substantial setbacks attributed to pronounced on- and off-target toxicities. To address these challenges, CRISPR/dCas9 technology is emerging as a potent tool for precise modulation of epigenetic mechanism. However, this technology involves co-expressing exogenous epigenetic modulator proteins, which presents technical challenges in preparation and delivery with potential undesirable side effects. Recently, our research demonstrated that Cas9 tagged with the Phe-Cys-Pro-Phe (FCPF)-peptide motif can be specifically targeted by perfluorobiphenyl (PFB) derivatives. Here, we integrated the FCPF-tag into dCas9 and established a chemically inducible platform for epigenome editing, called Chem-CRISPR/dCas9FCPF. We designed a series of chemical inhibitor-PFB conjugates targeting various epigenetic modulator proteins. Focusing on JQ1, a panBET inhibitor, we demonstrate that c-MYC-sgRNA-guided JQ1-PFB specifically inhibits BRD4 in close proximity to the c-MYC promoter/enhancer, thereby effectively repressing the intricate transcription networks orchestrated by c-MYC as compared with JQ1 alone. In conclusion, our Chem-CRISPR/dCas9FCPF platform significantly increased target specificity of chemical epigenetic inhibitors, offering a viable alternative to conventional fusion protein systems for epigenome editing.
- 24 September 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (19) , 11587-11601
Open AccessChem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing
Epigenetic aberration is one of the major driving factors in human cancer, often leading to acquired resistance to chemotherapies. Various small molecule epigenetic modulators have been reported. Nonetheless, outcomes from animal models and clinical trials have underscored the substantial setbacks attributed to pronounced on- and off-target toxicities. To address these challenges, CRISPR/dCas9 technology is emerging as a potent tool for precise modulation of epigenetic mechanism. However, this technology involves co-expressing exogenous epigenetic modulator proteins, which presents technical challenges in preparation and delivery with potential undesirable side effects. Recently, our research demonstrated that Cas9 tagged with the Phe-Cys-Pro-Phe (FCPF)-peptide motif can be specifically targeted by perfluorobiphenyl (PFB) derivatives. Here, we integrated the FCPF-tag into dCas9 and established a chemically inducible platform for epigenome editing, called Chem-CRISPR/dCas9FCPF. We designed a series of chemical inhibitor-PFB conjugates targeting various epigenetic modulator proteins. Focusing on JQ1, a panBET inhibitor, we demonstrate that c-MYC-sgRNA-guided JQ1-PFB specifically inhibits BRD4 in close proximity to the c-MYC promoter/enhancer, thereby effectively repressing the intricate transcription networks orchestrated by c-MYC as compared with JQ1 alone. In conclusion, our Chem-CRISPR/dCas9FCPF platform significantly increased target specificity of chemical epigenetic inhibitors, offering a viable alternative to conventional fusion protein systems for epigenome editing.
- Open Access
- 27 December 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (1) , 41
Molecular Marvels: Small Molecules Paving the Way for Enhanced Gene Therapy
In the rapidly evolving landscape of genetic engineering, the advent of CRISPR-Cas technologies has catalyzed a paradigm shift, empowering scientists to manipulate the genetic code with unprecedented accuracy and efficiency. Despite the remarkable capabilities inherent to CRISPR-Cas systems, recent advancements have witnessed the integration of small molecules to augment their functionality, introducing new dimensions to the precision and versatility of gene editing applications. This review delves into the synergy between CRISPR-Cas technologies based specifically on Cas9 and small-molecule drugs, elucidating the pivotal role of chemicals in optimizing target specificity and editing efficiency. By examining a diverse array of applications, ranging from therapeutic interventions to agricultural advancements, we explore how the judicious use of chemicals enhances the precision of CRISPR-Cas9-mediated genetic modifications. In this review, we emphasize the significance of small-molecule drugs in fine-tuning the CRISPR-Cas9 machinery, which allows researchers to exert meticulous control over the editing process. We delve into the mechanisms through which these chemicals bolster target specificity, mitigate off-target effects, and contribute to the overall refinement of gene editing outcomes. Additionally, we discuss the potential of chemical integration in expanding the scope of CRISPR-Cas9 technologies, enabling tailored solutions for diverse genetic manipulation challenges. As CRISPR-Cas9 technologies continue to evolve, the integration of small-molecule drugs emerges as a crucial avenue for advancing the precision and applicability of gene editing techniques. This review not only synthesizes current knowledge but also highlights future prospects, paving the way for a deeper understanding of the synergistic interplay between CRISPR-Cas9 systems and chemical modulators in the pursuit of more controlled and efficient genetic modifications.
- 27 December 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (1) , 41
Open AccessMolecular Marvels: Small Molecules Paving the Way for Enhanced Gene Therapy
In the rapidly evolving landscape of genetic engineering, the advent of CRISPR-Cas technologies has catalyzed a paradigm shift, empowering scientists to manipulate the genetic code with unprecedented accuracy and efficiency. Despite the remarkable capabilities inherent to CRISPR-Cas systems, recent advancements have witnessed the integration of small molecules to augment their functionality, introducing new dimensions to the precision and versatility of gene editing applications. This review delves into the synergy between CRISPR-Cas technologies based specifically on Cas9 and small-molecule drugs, elucidating the pivotal role of chemicals in optimizing target specificity and editing efficiency. By examining a diverse array of applications, ranging from therapeutic interventions to agricultural advancements, we explore how the judicious use of chemicals enhances the precision of CRISPR-Cas9-mediated genetic modifications. In this review, we emphasize the significance of small-molecule drugs in fine-tuning the CRISPR-Cas9 machinery, which allows researchers to exert meticulous control over the editing process. We delve into the mechanisms through which these chemicals bolster target specificity, mitigate off-target effects, and contribute to the overall refinement of gene editing outcomes. Additionally, we discuss the potential of chemical integration in expanding the scope of CRISPR-Cas9 technologies, enabling tailored solutions for diverse genetic manipulation challenges. As CRISPR-Cas9 technologies continue to evolve, the integration of small-molecule drugs emerges as a crucial avenue for advancing the precision and applicability of gene editing techniques. This review not only synthesizes current knowledge but also highlights future prospects, paving the way for a deeper understanding of the synergistic interplay between CRISPR-Cas9 systems and chemical modulators in the pursuit of more controlled and efficient genetic modifications.
- Open Access
- 12 December 2023
- Published by MDPI AG in Preprints.org
Molecular Marvels: Small Molecules Paving the Way for Enhanced Gene Therapy
In the rapidly evolving landscape of genetic engineering, the advent of CRISPR-Cas technologies has catalyzed a paradigm shift, empowering scientists to manipulate the genetic code with unprece-dented accuracy and efficiency. Despite the remarkable capabilities inherent to CRISPR-Cas sys-tems, recent advancements have witnessed the integration of small molecule to augment their functionality, introducing new dimensions to the precision and versatility of gene editing applica-tions. This review delves into the synergy between CRISPR-Cas technologies and small molecule drugs, elucidating the pivotal role of chemicals in optimizing target specificity and editing efficiency. By examining a diverse array of applications, ranging from therapeutic interventions to agricultural advancements, we explore how the judicious use of chemicals enhances the precision of CRISPR-Cas-mediated genetic modifications. In this review we emphasize the significance of small molecule drugs in fine-tuning the CRISPR-Cas machinery, which allows researchers to exert meticulous con-trol over the editing process. We delve into the mechanisms through which these chemicals bolster target specificity, mitigate off-target effects, and contribute to the overall refinement of gene edit-ing outcomes. Additionally, we discuss the potential of chemical integration in expanding the scope of CRISPR-Cas technologies, enabling tailored solutions for diverse genetic manipulation challenges. As CRISPR-Cas technologies continue to evolve, the integration of small molecule drugs emerges as a crucial avenue for advancing the precision and applicability of gene editing techniques. This re-view not only synthesizes current knowledge but also highlights future prospects, paving the way for a deeper understanding of the synergistic interplay between CRISPR-Cas systems and chemical modulators in the pursuit of more controlled and efficient genetic modifications.
- 12 December 2023
- Published by MDPI AG in Preprints.org
Open AccessMolecular Marvels: Small Molecules Paving the Way for Enhanced Gene Therapy
In the rapidly evolving landscape of genetic engineering, the advent of CRISPR-Cas technologies has catalyzed a paradigm shift, empowering scientists to manipulate the genetic code with unprece-dented accuracy and efficiency. Despite the remarkable capabilities inherent to CRISPR-Cas sys-tems, recent advancements have witnessed the integration of small molecule to augment their functionality, introducing new dimensions to the precision and versatility of gene editing applica-tions. This review delves into the synergy between CRISPR-Cas technologies and small molecule drugs, elucidating the pivotal role of chemicals in optimizing target specificity and editing efficiency. By examining a diverse array of applications, ranging from therapeutic interventions to agricultural advancements, we explore how the judicious use of chemicals enhances the precision of CRISPR-Cas-mediated genetic modifications. In this review we emphasize the significance of small molecule drugs in fine-tuning the CRISPR-Cas machinery, which allows researchers to exert meticulous con-trol over the editing process. We delve into the mechanisms through which these chemicals bolster target specificity, mitigate off-target effects, and contribute to the overall refinement of gene edit-ing outcomes. Additionally, we discuss the potential of chemical integration in expanding the scope of CRISPR-Cas technologies, enabling tailored solutions for diverse genetic manipulation challenges. As CRISPR-Cas technologies continue to evolve, the integration of small molecule drugs emerges as a crucial avenue for advancing the precision and applicability of gene editing techniques. This re-view not only synthesizes current knowledge but also highlights future prospects, paving the way for a deeper understanding of the synergistic interplay between CRISPR-Cas systems and chemical modulators in the pursuit of more controlled and efficient genetic modifications.
- 24 May 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 257, 115513
Development of a next-generation endogenous OCT4 inducer and its anti-aging effect in vivo
- 24 May 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 257, 115513
Development of a next-generation endogenous OCT4 inducer and its anti-aging effect in vivo
- Open Access
- 28 April 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (5) , 663
Recent Advances in Covalent Drug Discovery
In spite of the increasing number of biologics license applications, the development of covalent inhibitors is still a growing field within drug discovery. The successful approval of some covalent protein kinase inhibitors, such as ibrutinib (BTK covalent inhibitor) and dacomitinib (EGFR covalent inhibitor), and the very recent discovery of covalent inhibitors for viral proteases, such as boceprevir, narlaprevir, and nirmatrelvir, represent a new milestone in covalent drug development. Generally, the formation of covalent bonds that target proteins can offer drugs diverse advantages in terms of target selectivity, drug resistance, and administration concentration. The most important factor for covalent inhibitors is the electrophile (warhead), which dictates selectivity, reactivity, and the type of protein binding (i.e., reversible or irreversible) and can be modified/optimized through rational designs. Furthermore, covalent inhibitors are becoming more and more common in proteolysis, targeting chimeras (PROTACs) for degrading proteins, including those that are currently considered to be ‘undruggable’. The aim of this review is to highlight the current state of covalent inhibitor development, including a short historical overview and some examples of applications of PROTAC technologies and treatment of the SARS-CoV-2 virus.
- 28 April 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (5) , 663
Open AccessRecent Advances in Covalent Drug Discovery
In spite of the increasing number of biologics license applications, the development of covalent inhibitors is still a growing field within drug discovery. The successful approval of some covalent protein kinase inhibitors, such as ibrutinib (BTK covalent inhibitor) and dacomitinib (EGFR covalent inhibitor), and the very recent discovery of covalent inhibitors for viral proteases, such as boceprevir, narlaprevir, and nirmatrelvir, represent a new milestone in covalent drug development. Generally, the formation of covalent bonds that target proteins can offer drugs diverse advantages in terms of target selectivity, drug resistance, and administration concentration. The most important factor for covalent inhibitors is the electrophile (warhead), which dictates selectivity, reactivity, and the type of protein binding (i.e., reversible or irreversible) and can be modified/optimized through rational designs. Furthermore, covalent inhibitors are becoming more and more common in proteolysis, targeting chimeras (PROTACs) for degrading proteins, including those that are currently considered to be ‘undruggable’. The aim of this review is to highlight the current state of covalent inhibitor development, including a short historical overview and some examples of applications of PROTAC technologies and treatment of the SARS-CoV-2 virus.
- Open Access
- 3 December 2021
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 221 (1)
pVHL-mediated SMAD3 degradation suppresses TGF-β signaling
Transforming growth factor β (TGF-β) signaling plays a fundamental role in metazoan development and tissue homeostasis. However, the molecular mechanisms concerning the ubiquitin-related dynamic regulation of TGF-β signaling are not thoroughly understood. Using a combination of proteomics and an siRNA screen, we identify pVHL as an E3 ligase for SMAD3 ubiquitination. We show that pVHL directly interacts with conserved lysine and proline residues in the MH2 domain of SMAD3, triggering degradation. As a result, the level of pVHL expression negatively correlates with the expression and activity of SMAD3 in cells, Drosophila wing, and patient tissues. In Drosophila, loss of pVHL leads to the up-regulation of TGF-β targets visible in a downward wing blade phenotype, which is rescued by inhibition of SMAD activity. Drosophila pVHL expression exhibited ectopic veinlets and reduced wing growth in a similar manner as upon loss of TGF-β/SMAD signaling. Thus, our study demonstrates a conserved role of pVHL in the regulation of TGF-β/SMAD3 signaling in human cells and Drosophila wing development.
- 3 December 2021
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 221 (1)
Open AccesspVHL-mediated SMAD3 degradation suppresses TGF-β signaling
Transforming growth factor β (TGF-β) signaling plays a fundamental role in metazoan development and tissue homeostasis. However, the molecular mechanisms concerning the ubiquitin-related dynamic regulation of TGF-β signaling are not thoroughly understood. Using a combination of proteomics and an siRNA screen, we identify pVHL as an E3 ligase for SMAD3 ubiquitination. We show that pVHL directly interacts with conserved lysine and proline residues in the MH2 domain of SMAD3, triggering degradation. As a result, the level of pVHL expression negatively correlates with the expression and activity of SMAD3 in cells, Drosophila wing, and patient tissues. In Drosophila, loss of pVHL leads to the up-regulation of TGF-β targets visible in a downward wing blade phenotype, which is rescued by inhibition of SMAD activity. Drosophila pVHL expression exhibited ectopic veinlets and reduced wing growth in a similar manner as upon loss of TGF-β/SMAD signaling. Thus, our study demonstrates a conserved role of pVHL in the regulation of TGF-β/SMAD3 signaling in human cells and Drosophila wing development.